Bone health in cancer: ESMO Clinical Practice Guidelines
Robert E. Coleman, Peyman Hadji, Jean‐Jacques Body, Daniele Santini, Edward Chow, Evangelos Terpos, Stéphane Oudard, Øyvind S. Bruland, Patrick Flamen, Andreas Kurth, Catherine Van Poznak, Matti Aapro, Karin Jordan
Abstract
•The clinical course of advanced cancer for many patients with bone metastases can be transformed through optimum multidisciplinary management.•Bone-targeted agents significantly reduce skeletal morbidity in patients with bone metastases across tumour types and should be part of standard treatment.•Treatment-induced bone loss increases fracture risk and may require use of a bone-targeted agent in addition to lifestyle modifications.•The addition of a bisphosphonate to standard adjuvant therapies for postmenopausal early breast cancer reduces bone recurrence and improves survival.